超快速乳腺动态增强MRI的强化时间:肿瘤侵袭性的潜在影像生物标志物
本研究纳入2017年1月至8月274例连续乳腺癌患者,分析超快速MRI强化时间(TTE)与病理特征的相关性。浸润性癌TTE短于原位癌,且大肿瘤、高级别、HER2阳性、高Ki-67者TTE更短;最大斜率与强化率在各临床病理特征间无差异。
要点
- 浸润性乳腺癌超快速MRI的TTE短于原位癌(p<0.001)。
- 浸润性癌中,大肿瘤、高级别、HER2阳性及高Ki-67者TTE更短。
- 最大斜率与强化率在各临床病理特征间无差异。
核心结论
- 超快速MRI测得的中位TTE在浸润性癌或侵袭性强的肿瘤中分别短于原位癌或侵袭性弱的肿瘤。
研究设计与样本
- 研究纳入2017年1月至8月274例连续乳腺癌患者(平均年龄53.5岁,范围25-80岁),均行超快速MRI并后续手术。
- 超快速MRI采用TWIST-VIBE或4D TRAK-3D TFE序列采集,从超快速MRI推导TTE和最大斜率(MS)。
- 采用重复测量方差分析、Mann-Whitney U检验和Kruskal-Wallis H检验比较不同组织学类型、组织学分级、ER/PR/HER2状态、Ki-67水平及肿瘤亚型间的中位TTE、MS和SER。
- TTE计算采用组内相关系数(ICC)评估观察者间变异。
诊断标准与关键数值
- 浸润性癌中位TTE短于原位癌(p<0.001)。
- 浸润性癌中,大肿瘤TTE短于小肿瘤(p=0.001)。
- 高组织学分级/高核级癌TTE短于低至中级别癌(p<0.001和p<0.001)。
- HER2阳性癌TTE短于HER2阴性癌(p=0.001)。
- 高Ki-67癌中位TTE短于低Ki-67癌(p<0.001)。
临床应用与阅片要点
- 超快速MRI的TTE可能作为反映乳腺癌侵袭性的影像生物标志物。
- TTE观察者间一致性为中等(ICC=0.516),判读时需注意。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study was conducted in order to investigate whether there is a correlation between the time-to-enhancement (TTE) in ultrafast MRI and histopathological characteristics of breast cancers.
METHODS: Between January and August 2017, 274 consecutive breast cancer patients (mean age, 53.5 years; range, 25-80 years) who underwent ultrafast MRI and subsequent surgery were included for analysis. Ultrafast MRI scans were acquired using TWIST-VIBE or 4D TRAK-3D TFE sequences. TTE and maximum slope (MS) were derived from the ultrafast MRI. The repeated measures ANOVA, Mann-Whitney U test and Kruskal-Wallis H test were performed to compare the median TTE, MS and SER according to histologic type, histologic grade, ER/PR/HER2 positivity, level of Ki-67 and tumour subtype. For TTE calculation, intraclass correlation coefficient (ICC) was used to evaluate interobserver variability.
RESULTS: The median TTE of invasive cancers was shorter than that of in situ cancers (p < 0.001). In invasive cancers, large tumours showed shorter TTE than small tumours (p = 0.001). High histologic/nuclear grade cancers had shorter TTE than low to intermediate grade cancers (p < 0.001 and p < 0.001). HER2-positive cancers showed shorter TTE than HER2-negative cancers (p = 0.001). The median TTE of cancers with high Ki-67 was shorter than that of cancers with low Ki-67 (p < 0.001). ICC between two readers showed moderate agreement (0.516). No difference was found in the median MS or SER values according to the clinicopathologic features.
CONCLUSIONS: The median TTE of breast cancer in ultrafast MRI was shorter in invasive or aggressive tumours than in in situ cancer or less aggressive tumours, respectively.
KEY POINTS: • Invasive breast tumours show a shorter TTE in ultrafast DCE-MRI than in situ cancers. • A shorter TTE in ultrafast DCE-MRI is associated with breast tumours of a large size, high histologic or nuclear grade, PR negativity, HER2 positivity and high Ki-67 level.
引用
- Shin SU, Cho N, Kim SY, et al. Time-to-enhancement at ultrafast breast DCE-MRI: potential imaging biomarker of tumour aggressiveness. Eur Radiol. 2020. PMID: 32144456. doi:10.1007/s00330-020-06693-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。